DZ Bank’s Heron Therapeutics HRTX Stock Holding History

DZ Bank’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,062	Closed	-$361K	–	950
2018 Q1	$361K	Buy	+13,062	New	+$296K	﹤0.01%	842

Other funds holding HRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

DZ Bank's HRTX Position: Q2 2018 in Review

DZ Bank sold out of Heron Therapeutics (HRTX) in Q2 2018, closing a stake of 13,062 shares — an estimated $361K sold.

DZ Bank first reported a position in HRTX in Q1 2018 and held it in 1 quarter. The position peaked at $361K in Q1 2018. 196 funds tracked by Wall St. Rank hold HRTX as of Q2 2018.

DZ Bank reported no remaining Heron Therapeutics position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 13,062 Heron Therapeutics shares in Q2 2018, an estimated $361K.
DZ Bank first reported a position in Heron Therapeutics in Q1 2018 and held it in 1 quarter.
DZ Bank's Heron Therapeutics position peaked at $361K in Q1 2018.
196 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.